These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26311812)

  • 1. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
    Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
    J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
    Zhang C; Wang X; Cheng R; Zhong Z
    Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
    Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
    J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
    Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
    Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib.
    Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
    Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
    Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
    Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
    Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
    Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
    Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
    Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
    Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
    J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
    Jackson S; Agbana P; Kim KB; Bae Y
    J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
    Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
    Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
    Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W
    J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.